These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 8507916)

  • 1. The use of toxins to elucidate neural function and disease.
    Schapira AH
    Curr Opin Neurol Neurosurg; 1993 Jun; 6(3):448-51. PubMed ID: 8507916
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Secondary (toxic) parkinsonism as model of Parkinson's disease.
    Riederer P; Sofic E; Heuschneider G; Benedetti MS; Dostert P
    Funct Neurol; 1988; 3(4):449-57. PubMed ID: 3072280
    [No Abstract]   [Full Text] [Related]  

  • 3. [Experimental models of Parkinson's disease].
    Féger J; Pessigliore M; François C; Tremblay L; Hirsch E
    Ann Pharm Fr; 2002 Jan; 60(1):3-21. PubMed ID: 11976545
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The MPTP model of Parkinson's disease.
    Smeyne RJ; Jackson-Lewis V
    Brain Res Mol Brain Res; 2005 Mar; 134(1):57-66. PubMed ID: 15790530
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Do environmental toxins cause Parkinson's disease? A critical review.
    Tanner CM; Langston JW
    Neurology; 1990 Oct; 40(10 Suppl 3):suppl 17-30; discussion 30-1. PubMed ID: 2215971
    [No Abstract]   [Full Text] [Related]  

  • 6. Experimental models of Parkinson's disease: insights from many models.
    Tolwani RJ; Jakowec MW; Petzinger GM; Green S; Waggie K
    Lab Anim Sci; 1999 Aug; 49(4):363-71. PubMed ID: 10480640
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The experimental reproduction of catecholamine-deficient states and the problem of parkinsonism (the theoretical and practical aspects)].
    Voloshin MIa
    Neirofiziologiia; 1990; 22(3):401-14. PubMed ID: 2169036
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Experimental models of Parkinson's disease.
    Beal MF
    Nat Rev Neurosci; 2001 May; 2(5):325-34. PubMed ID: 11331916
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Toxins, genetics, and Parkinson's disease: the role of N-acetyltransferase 2.
    Bandmann O; Vaughan J; Holmans PA; Marsden CD; Wood NW
    Adv Neurol; 1999; 80():199-204. PubMed ID: 10410722
    [No Abstract]   [Full Text] [Related]  

  • 10. Neuroprotective effect of arundic acid, an astrocyte-modulating agent, in mouse brain against MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) neurotoxicity.
    Himeda T; Kadoguchi N; Kamiyama Y; Kato H; Maegawa H; Araki T
    Neuropharmacology; 2006 Mar; 50(3):329-44. PubMed ID: 16303147
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chronic inhalation of rotenone or paraquat does not induce Parkinson's disease symptoms in mice or rats.
    Rojo AI; Cavada C; de Sagarra MR; Cuadrado A
    Exp Neurol; 2007 Nov; 208(1):120-6. PubMed ID: 17880941
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Metabolic activation of azaheterocyclics induced dopaminergic toxicity: possible candidate neurotoxins underlying idiopathic Parkinson's disease].
    Matsubara K
    Nihon Hoigaku Zasshi; 1998 Oct; 52(5):301-5. PubMed ID: 10077975
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Olfactory impairment and Parkinson's disease-like symptoms observed in the common marmoset following administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
    Miwa T; Watanabe A; Mitsumoto Y; Furukawa M; Fukushima N; Moriizumi T
    Acta Otolaryngol Suppl; 2004 Aug; (553):80-4. PubMed ID: 15277042
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned model of parkinson's disease, with emphasis on mice and nonhuman primates.
    Jakowec MW; Petzinger GM
    Comp Med; 2004 Oct; 54(5):497-513. PubMed ID: 15575363
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A lot of "excitement' about neurodegeneration.
    Taylor R
    Science; 1991 Jun; 252(5011):1380-1. PubMed ID: 1828617
    [No Abstract]   [Full Text] [Related]  

  • 16. Thirty years of dopamine research.
    Carlsson A
    Adv Neurol; 1993; 60():1-10. PubMed ID: 8093570
    [No Abstract]   [Full Text] [Related]  

  • 17. Neurotrophic actions of the novel AMPA receptor potentiator, LY404187, in rodent models of Parkinson's disease.
    O'Neill MJ; Murray TK; Whalley K; Ward MA; Hicks CA; Woodhouse S; Osborne DJ; Skolnick P
    Eur J Pharmacol; 2004 Feb; 486(2):163-74. PubMed ID: 14975705
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sensitivity of zebrafish to environmental toxins implicated in Parkinson's disease.
    Bretaud S; Lee S; Guo S
    Neurotoxicol Teratol; 2004; 26(6):857-64. PubMed ID: 15451049
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The risk is in the air: Intranasal administration of MPTP to rats reproducing clinical features of Parkinson's disease.
    Prediger RD; Batista LC; Medeiros R; Pandolfo P; Florio JC; Takahashi RN
    Exp Neurol; 2006 Dec; 202(2):391-403. PubMed ID: 16908021
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Granulocyte-macrophage colony-stimulating factor promotes survival of dopaminergic neurons in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced murine Parkinson's disease model.
    Kim NK; Choi BH; Huang X; Snyder BJ; Bukhari S; Kong TH; Park H; Park HC; Park SR; Ha Y
    Eur J Neurosci; 2009 Mar; 29(5):891-900. PubMed ID: 19245369
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.